Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...

New data hint at a role for the AS01 adjuvant in vaccines for herpes zoster and respiratory syncytial virus in protecting ...

Chemists welcome plans for NHS patients to access weight-loss jabs but warn it will need sufficient funding ...

JSE-listed poultry producer Astral Foods has been given official approval to begin vaccinating its broiler breeding stock ...

The group cast aside evidence-based science in favor of anti-vaccine propaganda and dangerous falsehoods that will hurt ...

Moderna shares rose on the increased effectiveness of its flu vaccine in late-stage trials, bring the biotech company closer ...

Presented by Vaccinate Your Family{beacon} Health Care Health Care   The Big Story Senate set to vote on amendment rolling ...

The Trump administration’s new vaccine advisers endorsed this fall's flu vaccines late last week, but only those that don't ...

Moderna’s experimental mRNA-based flu vaccine demonstrated a stronger immune response than a currently available standard flu shot in a late-stage phase 3 trial, clearing a path for regulatory ...

Newborns are at risk for serious complications from influenza infections but are not eligible for vaccination until they are ...

Moderna today reported promising relative vaccine efficacy (rVE) findings from a phase 3 trial of its seasonal mRNA flu ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.